Qysmia, the combination of these two medications, is an oral medication designed as an adjunct to lifestyle modifications when managing obesity
Its also important that patients dont pin all their health success on one medication. The reasons patients end up in the non-responder category can vary and sometimes, there is more than one factor
Its broader medication menu is worth understanding for patients whose needs extend beyond a single GLP-1 option
Higher expectations - Mounjaro at its highest dose (15mg) produces an average weight loss of 22.5% of body weight at 72 weeks, compared to 20.7% for Wegovy at its highest dose
The decision to continue, adjust, or discontinue Ozempic should be individualised, recognising that for many patients, the metabolic benefits significantly outweigh manageable gastrointestinal symptoms, particularly when appropriate supportive measures are implemented